| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.YJMCC.2007.01.003 |
| P8608 | Fatcat ID | release_lat5dy4juba2hgcfkl5jhwr57m |
| P932 | PMC publication ID | 1945057 |
| P698 | PubMed publication ID | 17300800 |
| P5875 | ResearchGate publication ID | 6504253 |
| P2093 | author name string | Roger J Hajjar | |
| Djamel Lebeche | |||
| Woo Jin Park | |||
| Yoshiaki Kawase | |||
| Susumu Sakata | |||
| Federica del Monte | |||
| Dongtak Jeong | |||
| Yoshiaki Takewa | |||
| Elie R Chemaly | |||
| Krisztina Zsebo | |||
| Li Fan Liang | |||
| Naoya Sakata | |||
| Richard Peluso | |||
| Tsuyoshi Tsuji | |||
| Yuri Sakata | |||
| P2860 | cites work | Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a | Q22010899 |
| Molecular basis of cardiac performance. Plasticity of the myocardium generated through protein isoform switches | Q24621025 | ||
| Calcium fluxes involved in control of cardiac myocyte contraction | Q28144050 | ||
| Cardiac excitation-contraction coupling | Q28216347 | ||
| Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure | Q28354203 | ||
| In vivo acceleration of heart relaxation performance by parvalbumin gene delivery | Q30501538 | ||
| Prospects for gene therapy for heart failure | Q33881236 | ||
| Myofilament calcium regulation in human myocardium | Q34074806 | ||
| Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure | Q34978011 | ||
| Clinical use of inotropic therapy for heart failure: looking backward or forward? Part II: chronic inotropic therapy | Q35186772 | ||
| Abnormalities in intracellular calcium regulation and contractile function in myocardium from dogs with pacing-induced heart failure | Q35599387 | ||
| Modulation of ventricular function through gene transfer in vivo | Q36067860 | ||
| Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors | Q37596958 | ||
| Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling | Q37682472 | ||
| Ventricular energetics | Q37911389 | ||
| Myosin isoenzyme redistribution in chronic heart overload | Q39575052 | ||
| Characterization of cardiac sarcoplasmic reticulum dysfunction during short-term, normothermic, global ischemia | Q41536389 | ||
| Cardiac dysfunction in terms of left ventricular mechanical work and energetics in hypothyroid rats | Q44068487 | ||
| In vivo gene transfer of parvalbumin improves diastolic function in aged rat hearts | Q45882717 | ||
| Mechanical and metabolic rescue in a type II diabetes model of cardiomyopathy by targeted gene transfer | Q46964433 | ||
| Gene transfer of parvalbumin improves diastolic dysfunction in senescent myocytes | Q47406744 | ||
| Relationship between Na+-Ca2+-exchanger protein levels and diastolic function of failing human myocardium | Q48749719 | ||
| Restoration of diastolic function in senescent rat hearts through adenoviral gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase. | Q51417559 | ||
| Normal myocardial function and energetics in volume-overload hypertrophy in the cat. | Q53711704 | ||
| Mechanisms for the abnormal energetics of pressure-induced hypertrophy of cat myocardium. | Q54402659 | ||
| Myocardial oxygen consumption during experimental hypertrophy and congestive heart failure | Q68506541 | ||
| Decreased contractile efficiency and increased nonmechanical energy cost in hyperthyroid rabbit heart. Relation between O2 consumption and systolic pressure-volume area or force-time integral | Q68737367 | ||
| Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure | Q69122833 | ||
| Altered calcium handling in experimental pressure-overload hypertrophy in the ferret | Q69979818 | ||
| Decreased energy reserve in an animal model of dilated cardiomyopathy. Relationship to contractile performance | Q71056599 | ||
| Alterations of Sarcoplasmic Reticulum Proteins in Failing Human Dilated Cardiomyopathy | Q71974451 | ||
| Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium | Q72133115 | ||
| Altered stoichiometry of FKBP12.6 versus ryanodine receptor as a cause of abnormal Ca(2+) leak through ryanodine receptor in heart failure | Q73108723 | ||
| Upregulation of Na(+)/Ca(2+) exchanger expression and function in an arrhythmogenic rabbit model of heart failure | Q73204498 | ||
| Pharmacological modulation of pressure-overload cardiac hypertrophy: changes in ventricular function, extracellular matrix, and gene expression | Q73804365 | ||
| No dependency of a new index for oxygen cost of left ventricular contractility on heart rates in the blood-perfused excised rat heart | Q74019123 | ||
| Contribution of abnormal sarcoplasmic reticulum ATPase activity to systolic and diastolic dysfunction in human heart failure | Q77502354 | ||
| Na/Ca exchange in heart failure: contractile dysfunction and arrhythmogenesis | Q78719599 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | aorta | Q101004 |
| P304 | page(s) | 852-861 | |
| P577 | publication date | 2007-01-10 | |
| P1433 | published in | Journal of Molecular and Cellular Cardiology | Q2061932 |
| P1476 | title | Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins | |
| P478 | volume | 42 |
| Q28297096 | AAV-mediated gene therapy for heart failure: enhancing contractility and calcium handling |
| Q34248473 | AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model |
| Q34132686 | Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. |
| Q37766138 | Advances in gene-based therapy for heart failure |
| Q37239340 | Alterations in ryanodine receptors and related proteins in heart failure |
| Q35116100 | Altered myocardial calcium cycling and energetics in heart failure--a rational approach for disease treatment |
| Q36837270 | Altered sarcoplasmic reticulum calcium cycling--targets for heart failure therapy |
| Q36313661 | Ameliorated stress related proteins are associated with improved cardiac function by sarcoplasmic reticulum calcium ATPase gene transfer in heart failure |
| Q51869172 | Benefit of SERCA2a gene transfer to vascular endothelial and smooth muscle cells: a new aspect in therapy of cardiovascular diseases. |
| Q34195822 | Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure |
| Q27026716 | Calcium mishandling in diastolic dysfunction: mechanisms and potential therapies |
| Q37364786 | Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. |
| Q38916981 | Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial |
| Q34409721 | Cardiac Gene Therapy |
| Q46952259 | Cardiac contractility modulation therapy in advanced systolic heart failure |
| Q37811189 | Cardiac gene therapy with SERCA2a: From bench to bedside |
| Q35174923 | Cardiac gene transfer of short hairpin RNA directed against phospholamban effectively knocks down gene expression but causes cellular toxicity in canines |
| Q27691424 | Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure |
| Q45872017 | Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors |
| Q38788217 | Current Methods in Cardiac Gene Therapy: Overview |
| Q37299072 | Designing heart performance by gene transfer. |
| Q43544082 | Differential patterns of replacement and reactive fibrosis in pressure and volume overload are related to the propensity for ischaemia and involve resistin |
| Q89782554 | Dysregulation of Calcium Handling in Duchenne Muscular Dystrophy-Associated Dilated Cardiomyopathy: Mechanisms and Experimental Therapeutic Strategies |
| Q37685861 | Effect of bortezomib on the efficacy of AAV9.SERCA2a treatment to preserve cardiac function in a rat pressure-overload model of heart failure. |
| Q37950457 | Endogenous migration modulators as parent compounds for the development of novel cardiovascular and anti-inflammatory drugs |
| Q34092888 | Enhanced basal contractility but reduced excitation-contraction coupling efficiency and beta-adrenergic reserve of hearts with increased Cav1.2 activity |
| Q57030935 | Epigallocatechin-3 gallate prevents pressure overload-induced heart failure by up-regulating SERCA2a via histone acetylation modification in mice |
| Q38025012 | Gene and cytokine therapy for heart failure: molecular mechanisms in the improvement of cardiac function |
| Q34130135 | Gene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitation |
| Q33804951 | Gene therapies for arrhythmias in heart failure |
| Q83556143 | Gene therapy for heart failure |
| Q38073152 | Gene therapy for heart failure: where do we stand? |
| Q36953151 | Gene therapy for the treatment of heart failure: promise postponed |
| Q30539495 | Gene transfer in skeletal and cardiac muscle using recombinant adeno-associated virus |
| Q51116860 | Impaired left ventricular mechanical and energetic function in mice after cardiomyocyte-specific excision of Serca2. |
| Q38830312 | Importance of SERCA2a on early isolated diastolic dysfunction induced by supravalvular aortic stenosis in rats |
| Q45886178 | Intramyocardial injection of SERCA2a-expressing lentivirus improves myocardial function in doxorubicin-induced heart failure |
| Q97569409 | Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device - the SERCA-LVAD TRIAL |
| Q43110528 | Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy |
| Q37162555 | Mechanical work and energetic analysis of eccentric cardiac remodeling in a volume overload heart failure in rats |
| Q37101211 | Mechanisms of disease: ion channel remodeling in the failing ventricle |
| Q36042518 | Mechanisms of ventricular arrhythmias: a dynamical systems-based perspective |
| Q26823061 | Model-specific selection of molecular targets for heart failure gene therapy |
| Q24337593 | Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome |
| Q37643467 | Molecular cardiology in translation: gene, cell and chemical-based experimental therapeutics for the failing heart. |
| Q53073861 | Myocardial reverse remodeling after pressure unloading is associated with maintained cardiac mechanoenergetics in a rat model of left ventricular hypertrophy. |
| Q51370275 | Myocardial twitch duration and the dependence of oxygen consumption on pressure-volume area: experiments and modelling. |
| Q37068663 | Pathological hypertrophy amelioration by PRAS40-mediated inhibition of mTORC1 |
| Q46022665 | Pim-1 regulates cardiomyocyte survival downstream of Akt. |
| Q36951008 | Plasticity of surface structures and β(2)-adrenergic receptor localization in failing ventricular cardiomyocytes during recovery from heart failure |
| Q30383732 | Post-translational Modifications in Heart Failure: Small Changes, Big Impact |
| Q36497159 | Potential of gene therapy as a treatment for heart failure |
| Q34627450 | Progesterone modulates SERCA2a expression and function in rabbit cardiomyocytes |
| Q39356341 | Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases |
| Q45868599 | Pulmonary venous hypertension and mechanical strain stimulate monocyte chemoattractant protein-1 release and structural remodelling of the lung in human and rodent chronic heart failure models |
| Q37822275 | Refilling Intracellular Calcium Stores |
| Q30604007 | Regulation of metabolism in individual mitochondria during excitation-contraction coupling |
| Q34757960 | Rescuing the failing heart by targeted gene transfer |
| Q37964927 | Reverse remodeling in heart failure--mechanisms and therapeutic opportunities |
| Q92175147 | Roles and mechanisms of SUMOylation on key proteins in myocardial ischemia/reperfusion injury |
| Q37418216 | SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope. |
| Q34025110 | SERCA2a gene transfer enhances eNOS expression and activity in endothelial cells |
| Q35183186 | SERCA2a gene transfer improves electrocardiographic performance in aged mdx mice |
| Q37676218 | Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure |
| Q38016716 | Sarcoplasmic reticulum and calcium cycling targeting by gene therapy |
| Q30654383 | Small-molecule activation of SERCA2a SUMOylation for the treatment of heart failure |
| Q36320912 | Stroke volume-to-wall stress ratio as a load-adjusted and stiffness-adjusted indicator of ventricular systolic performance in chronic loading |
| Q53580927 | Targeted gene transfer increases contractility and decreases oxygen cost of contractility in normal rat hearts. |
| Q35763705 | Targeting cardiomyocyte Ca2+ homeostasis in heart failure |
| Q37229784 | The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases |
| Q90465039 | Unique Ca2+-Cycling Protein Abundance and Regulation Sustains Local Ca2+ Releases and Spontaneous Firing of Rabbit Sinoatrial Node Cells |
| Q37793527 | What Causes a Broken Heart—Molecular Insights into Heart Failure |
Search more.